Skip to main content

CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer (Grand Rounds)

A CME-certified, ABIM MOC-eligible Activity

Click here to complete your registration.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.


Welcome and Introduction
Personalized Treatment for Progressive HER2-Positive Breast Cancer
New Horizons in HER2-Positive Breast Cancer Care
Q&A Session and Activity Roundup

The introduction of CDK4/6 inhibitors into the treatment of HR-positive, HER2-negative metastatic breast cancer (mBC) resulted in a paradigm shift, and these agents are now considered the gold standard for first-line treatment. Since their approval, robust real-world data have been collected on the safety and efficacy of these agents outside the confines of a clinical trial. This includes new information on optimal selection between CDK4/6 inhibitors based on patient and disease characteristics and how best to sequence treatments across multiple lines of therapy.

This activity, CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer, will provide oncology practitioners with up-to-date information on the use of CDK4/6 inhibitors in the treatment of patients with HR-positive, HER2-negative mBC, including an in-depth evaluation of current clinical trial data and real-world experience with available CDK4/6 inhibitors and strategies for developing personalized patient treatment plans that take into consideration patient and disease characteristics such as comorbidities, menopausal status, and site of metastasis.

Megan Kruse, MD
Staff, Breast Medical Oncology, Cleveland Clinic
Assistant Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland, OH

Ruth O'Regan, MD

Charles A. Dewey Endowed Professor of Medicine
Chair, Department of Medicine
University of Rochester Medical Center
Physician-in-Chief, Strong Memorial Hospital
Associate Director of Education and Mentoring
Wilmot Cancer Institute
Rochester, NY

The intended audience for this educational initiative is oncologists, nurses, and other clinicians involved in the treatment of patients with metastatic breast cancer.

At the conclusion of this activity, participants should be able to:

  • Evaluate currently available CDK4/6 inhibitors for the treatment of HR+/HER2- metastatic breast cancer (mBC) based on clinical trial safety and efficacy data
  • Summarize outcomes of real-world studies and experiences with CDK4/6 inhibitors in HR+/HER2- mBC
  • Develop patient-personalized treatment plans for HR+/HER2- mBC that incorporate clinical trial and real-world evidence, treatment guidelines, and patient characteristics

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

ABMS Lifelong Learning CME Activity
Family Medicine

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of the activity is vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships will be mitigated by PCME.

Disclosure and mitigation information will be made known to the participants prior to the start of the activity.

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

To ensure your computer is compatible for the live event, please perform a system check by clicking on the link or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.

  • 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
  • Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
  • 512 MB of RAM (1 GB recommended)
  • Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
  • 1.83 GHz Intel Core Duo or faster processor
  • 512 MB RAM (1 GB recommended)
  • Mac OS X 10.12, 10.13 and 10.14
  • Mozilla Firefox, Apple Safari, Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
  • The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later
  • Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods)
  • Google Android 4.4 or later
  • Apple iOS: iOS 8.1.2 or later

DSL/cable (wired connection recommended)

There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

Jointly provided by 

This program is supported by an educational grant from Novartis Pharmaceuticals Corporation.

PCME Privacy Policy